Gastric Cancer, MetastaticPhase 1/2NCT07509008
TROP2 CAR/IL-15 TGFBR2 KO NK Cells
TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
What the film says
This trial is for adults with advanced gastro-esophageal or other gastrointestinal cancers that are HER2 positive, after earlier treatment.
The idea: combine neratinib, a daily pill, with trastuzumab deruxtecan, given by vein on day one of each 21 day cycle. Small groups of patients receive rising doses of neratinib.
This phase 1 study plans 18 patients and looks for the maximum tolerated dose and recommended phase 2 dose. At Fox Chase Cancer Center in Philadelphia, Namrata Vijayvergia leads it.
Public record; not medical advice.
Sources behind this film
Adults; advanced gastro-esophageal or other GI cancers, HER2 positive, after prior treatment; Neratinib daily pill; trastuzumab deruxtecan by vein day 1 of 21 day cycle; Small groups receive rising neratinib doses; Phase 1; 18 patients; MTD and RP2D (+1 more lines)
The drug
Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
Patients must have progressed or been intolerant of at least one prior line of chemotherapy + HER2 directed therapy. A total of 18 patients will be enrolled with the plan to reach MTD and enroll any remaining patients at the RP2D to further define the toxicities and preliminary efficacy to help define the future studies with this combination. Patients will be enrolled in cohorts of 3 at each dose level (see SCHEMA).
The study
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in patients with metastatic or unresectable gastro-esophageal cancer that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+) and any other gastrointestinal cancer with HER2 expression with IHC3+.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.